Stifel Nicolaus Upgrades Amedisys (AMED) to Buy
More News related to AMED
- Amedisys (AMED) Releases Review Report from Marwood Group Advisory
- Amedisys Releases Report from Marwood Group Advisory
- Amedisys to Present at the Oppenheimer 20th Annual Healthcare Conference
- Stifel Nicolaus Upgrades Amedisys (AMED) to Buy
- Amedisys (AMED) options active after reaffirming FY2009 guidance
More News related to Upgrades
- TiVo (TIVO) and Google (GOOG) to Team Up in Audience Research Agreement
- Nanosphere (NSPH) Receives 510(k) from U.S. FDA to Update RVNATSP to Include Flu Cultured Clinical Isolates with H1N1 Virus
- ZAGG (ZAGG) Announces Exclusive Deal with T-Mobile Germany
- MDRNA (MRNA) Announces Expansion and Collaboration with VPC for RNAi-Based Therapeutics
- SuccessFactors (SFSF) Announces Mercy Health to Help Optimize Business Execution
Stifel Nicolaus upgrades Amedisys (Nasdaq: AMED) from Hold to Buy.
To see more analyst ratings on AMED Click Here.
Amedisys, Inc. provides home health and hospice services to the chronic, co-morbid, and aging American population.
Related Categories
UpgradesStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
